Menu

Obesity Research Pioneer Dies

Douglas Coleman, the biochemist and geneticist whose early experiments led to the discovery of leptin, has passed away at age 82.

Apr 28, 2014
Rina Shaikh-Lesko

JACKSON LABORATORYBiochemist and geneticist Douglas Coleman, who helped uncover the role of leptin in obesity, died last week (April 16) from complications of basal cell carcinoma. He was 82.

During the late 1960s and early 1970s, while working at the Jackson Laboratory in Bar Harbor, Maine, Coleman identified a blood-borne “satiety factor” linked to obesity and diabetes in mice. At the time, most researchers thought obesity was strictly behavior-related, leading many to doubt his results. By the 1990s, however, Jeffrey Friedman from the Rockefeller University in New York followed up on Coleman’s findings and identified the hormone leptin and its associated gene. Coleman and Friedman shared a Lasker Prize for this work in 2010, The New York Times reported. That same year, Thomson Reuters named Coleman a contender for the Nobel Prize in physiology or medicine, although he did not win.

“Doug was a scientist’s scientist and a good friend,” Friedman said in a statement.

Coleman was born in Stratford, Ontario, in 1931. He earned an undergraduate degree in chemistry from McMaster University in Hamilton, Ontario, and a PhD in biochemistry from the University of Wisconsin, Madison. In 1958, Coleman began working at the Jackson Lab, where he spent the remainder of his career. After retiring from research, he converted a plot of land he owned in Lamoine, Maine, into a nature preserve.

He is survived by two sons and one grandson.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.